Biochip Market Growth with Worldwide Industry Analysis to 2021

Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has become an indispensible part of biochip applications.

Biochip technology has been widely used in genetic engineering and analysis. These chips have DNA strands attached to the surface, and can detect samples with extremely small concentration. Genetic biochips or genechips have accelerated genome sequencing and are now being incorporated in devices for easy and rapid analysis. Scientists have developed biochip transponder which is placed under the skin to provide unique identification. Integration of biochip technology with genetic and protein research has facilitated rapid and accurate analysis. Application of microarray and microfluidic technology in veterinary diagnosis has increased considerably in the recent past. Biochips in animal health are used in disease diagnosis and genotyping.

Free Sample Report@ http://www.sa-brc.com/Global-Biochip-Market-Assessment--Forecast-2017-2021/up78

Increasing understanding of biomarkers and genetic makeup and their role in disease diagnosis and progression is expected to increase application of biochips in routine diagnosis. Majority of the overall biochips market is dominated by North America, Europe and Asia Pacific geographies. It is expected that more number of biotechnology research institutes would emerge in the near future owing to increased government funding and acknowledgement of success in biopharmaceutical research through regulatory approvals and new policy amendments.

From the clinical point-of-view, there is huge demand for rapid diagnosis and targeted therapy. Economic burden for diseases such as cancer, diabetes, cardiovascular and neurological diseases is increasing rapidly across the globe. National Cancer Institute, U.S. estimates over 1.68 million new cancer cases diagnosed in the U.S. in 2016. In U.K. 0.35 million new cancer cases were recorded as per Cancer Research U.K, while globally more than 8 million patients die due to cancer. According to World Health Organization (WHO) over 422 million individuals were recorded having diabetes in 2014 globally. Research also estimates that the prevalence of these chronic diseases is expected to rise in the coming years, which would provide necessary leverage for the biochip market growth.

Click For TOC@ http://www.sa-brc.com/Global-Biochip-Market-Assessment--Forecast-2017-2021/upcomingdetail78

ProtoArray human protein microarray by Thermo Fisher Scientific consists of over 9,000 unique human proteins and enables biomarker identification with concentration as low as 10 ?L. These systems also help in mapping protein-protein interaction for providing more insights to complex biochemical pathways. Other key players in the global biochip market are Agilent Technologies, Inc., Bio-Rad laboratories, Inc., PerkinElmer Inc., Randox Laboratories, Illumina, Inc., Thermo Fisher Scientific, Inc., Oxford Nanopore, VHLGenetics, Median Diagnostic, Inc. and others.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.